Genomic Testing Cooperative to Reveal 'Liquid Trace™' at ASCO, a Liquid Biopsy Test that Combines Cell-Free DNA with Targeted Transcriptome, and to Present Data on its Advanced AI for the Diagnosis of
businesswire.com
news
2022-06-01 00:00:00

IRVINE, Calif.--(BUSINESS WIRE)--Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the American Society of Clinical Oncology (ASCO) 2022 annual meeting data showcasing its new innovative approach to liquid biopsy testing that combines both cell-free-DNA (cfDNA) with cell-free RNA (cfRNA), Liquid Trace™. Liquid Trace tests both cfDNA and cfRNA not only improves sensitivity of the liquid biopsy but also provides transcriptome data that is enriched by various tumor markers (CA125, CA 15-3, CEA, etc) and makes it possible to perform liquid immunoprofiling by evaluating levels of CD19, CD20, CD33, CD4, CD8, etc.
